News | May 21, 2010

Biodegradable Stent Preserves Mechanical Strength


May 21, 2010 – Results of an in vivo study of 48 porcine arteries implanted with a biodegradable stent showed biodegradation is measurable and begins at the first day of implant. However, high radial strength is maintained during biodegradation.

These results were released this week by Arterial Remodeling Technologies (ART), which is developing bioresorbable coronary polylactic acid polymer stents that promote the natural remodeling of an injured artery after angioplasty.

Previous validating data regarding ART’s next-generation bioresorbable stent approach has been published in the January 2010 special supplement of EuroIntervention. The paper was authored by Antoine Lafont, M.D., Ph.D., Head, Interventional Cardiology Department, Georges Pompidou Hospital, Paris.

The stent is designed to provide an impermanent scaffold that will dismantle and loose its primary mechanical function after three months. This is the period when most experts say is it is necessary to permit the healing process to stabilize the artery following the trauma caused by an angioplasty. The complete resorption of all the polymer is estimated to occur within 18 months.

ART said its stent is designed to have several competitive benefits over existing bioresorbable stents in development. These include faster and smoother resorption, use of a non-crystalline polymer, better stress diffusion, and crack-free expansion. The ART device is designed for conventional balloon stent delivery and meets the market standard of 6 French compatibility.

For more information: www.art-stent.com


Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now